2026-11-13 · Notice · 2026-23141Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or EffectivenessExenatideOpen attributed record →
2026-08-24 · Notice · 2026-17222Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; AvailabilityLeuprolide + OctreotideOpen attributed record →
2026-08-20 · Notice · 2026-16998Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; RenewalExenatideOpen attributed record →
2026-07-29 · Notice · 2026-15285Product-Specific Guidances; Revised Draft Guidances for Industry; AvailabilityGlucagon + Liraglutide + Semaglutide + Teriparatide + Tirzepatide + VosoritideOpen attributed record →
2026-07-28 · Notice · 2026-15149Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for CommentsDalbavancinOpen attributed record →
2026-07-06 · Notice · 2026-13492Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or EffectivenessVasopressinOpen attributed record →
2026-06-26 · Notice · 2026-12937List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment PeriodLiraglutide + Semaglutide + TirzepatideOpen attributed record →
2026-06-03 · Notice · 2026-11062Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug ApplicationsVasopressinOpen attributed record →
2026-05-22 · Notice · 2026-10277Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; AvailabilityPalopegteriparatideOpen attributed record →
2026-05-01 · Notice · 2026-08552List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic ActGlucagon + Liraglutide + Semaglutide + TirzepatideOpen attributed record →
2026-04-30 · Notice · 2026-08435Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or EffectivenessSemaglutideOpen attributed record →
2026-04-22 · Rule · 2026-07863Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection SystemSetmelanotideOpen attributed record →
2026-04-16 · Notice · 2026-07361Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances ListBPC-157 + Emideltide + Epitalon + KPV + MOTS-c + Semax + TB-500Open attributed record →
2026-03-09 · Notice · 2026-04546Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug ApplicationsExenatideOpen attributed record →
2026-02-27 · Notice · 2026-03963Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; AvailabilityOctreotide + SemaglutideOpen attributed record →
2026-02-12 · Notice · 2026-02786Jeremy Spencer Brown: Final Debarment OrderSemaglutideOpen attributed record →
2025-12-19 · Notice · 2025-23409Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide)ElamipretideOpen attributed record →
2025-12-05 · Notice · 2025-22131Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; AvailabilityGlucagon + Liraglutide + Semaglutide + Teriparatide + Tirzepatide + VosoritideOpen attributed record →
2025-11-21 · Notice · 2025-20548Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; AvailabilityGlucagon + TirzepatideOpen attributed record →
2025-10-02 · Notice · 2025-19281Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for CommentsExenatide + LinaclotideOpen attributed record →
2025-10-02 · Notice · 2025-19345Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; AvailabilitySemaglutideOpen attributed record →
2025-09-24 · Notice · 2025-18453Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug ApplicationsBivalirudinOpen attributed record →
2025-08-26 · Notice · 2025-16269Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATHPalopegteriparatideOpen attributed record →
2025-08-04 · Notice · 2025-14683Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug ApplicationsExenatideOpen attributed record →
2025-06-20 · Notice · 2025-11314Determination of Regulatory Review Period for Purposes of Patent Extension; ZILBRYSQZilucoplanOpen attributed record →
2025-05-21 · Notice · 2025-09068Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; AvailabilityZilucoplanOpen attributed record →
2025-04-09 · Notice · 2025-0604821st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for CommentsDaptomycinOpen attributed record →
2025-01-21 · Rule · 2025-01226New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor AddressTriptorelinOpen attributed record →
2024-11-20 · Notice · 2024-27048Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; AvailabilityLiraglutideOpen attributed record →
2024-11-19 · Notice · 2024-26913Pfizer, Inc., et al.; Withdrawal of Approval of 26 New Drug ApplicationsDesmopressinOpen attributed record →
2024-10-31 · Notice · 2024-25391Product-Specific Guidances; Revised Draft Guidances for Industry; AvailabilityDesmopressinOpen attributed record →
2024-10-25 · Notice · 2024-24828Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances ListCJC-1295Open attributed record →
2024-09-25 · Notice · 2024-21941Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUETrofinetideOpen attributed record →
2024-09-18 · Notice · 2024-21241Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed ListIpamorelinOpen attributed record →
2024-09-06 · Notice · 2024-20062Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride InjectionElamipretideOpen attributed record →
2024-08-23 · Notice · 2024-18898Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650Exenatide + GlucagonOpen attributed record →